Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
PRDS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.22
N/A
NA
vs -0.08
Q2.22
+434%
0.48
vs -0.14
Q3.22
+297%
0.4
vs -0.20
Q4.22
+209%
0.41
vs -0.38
Q1.23
N/A
0.3
vs NA
Q2.23
-62%
0.18
vs 0.48
Sales Growth
YoY
Current
Estimates
Q1.22
NA
NA vs NA
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Q4.22
NA
NA vs NA
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Return on Equity
QoQ
Q3.21
+32%
0.32
vs -1.63
Q4.21
-5%
-0.05
vs 0.32
Q1.22
-9%
-0.09
vs -0.05
Q2.22
-12%
-0.12
vs -0.09
Q3.22
-11%
-0.11
vs -0.12
Q4.22
-28%
-0.28
vs -0.11
Q1.23
-9%
-0.09
vs -0.28
Q2.23
-7%
-0.07
vs -0.09
Institutionnal Ownership
QoQ
Q4.21
41
41
vs NA
NA
Q1.22
57
57
vs 41
39%
Q2.22
65
65
vs 57
14%
Q3.22
63
63
vs 65
-3%
Q4.22
63
63
vs 63
NA
Q1.23
59
59
vs 63
-6%
Q2.23
59
59
vs 59
NA
Q3.23
1
1
vs 59
-98%
globenewswire.com
8 hours ago
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
NASDAQ
0.02 ( 0.93%)
After-hours 0.00$
-2.18 (-100.00%)
Relative Strenght
55
Volume Buzz
322%
Earning Acce
Yes
Dist 52w H.
41%Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
JMP Securities
initialisePrevious: Not converted
2022-12-13
Now: Market Outperform
Relative Strength
PRDS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
